Interestingly, TET2, an enzyme that catalyzes DNA demethylation, is a tumor suppressor in prostate cancer and is frequently mutated, with loss of TET2 expression associated with cancer progression and reduced patient survival (69, 88). Here, TET2 is linked to neoplasm.